Amend 005 - Hepatitis A and B Adult and Pediatric - GlaxoSmithKline Inc.
Status Awarded
Contract number E60PH-22HEAB/001/PH
Solicitation number E60PH-22HEAB/A
Publication date
Contract award date
Last amendment date
Amendment value
Status Awarded
Contract number E60PH-22HEAB/001/PH
Solicitation number E60PH-22HEAB/A
Publication date
Contract award date
Last amendment date
Amendment value
This contract was awarded to:
The contract will be for a period of 36 month(s), from 2022/03/03 to 2025/03/31.
CAD 13,587,803.61
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below: